HT-0712

HT-0712
Systematic (IUPAC) name
(3S,5S)-5-(3-(Cyclopentyloxy)-4-methoxyphenyl)-3-(3-methylbenzyl)piperidin-2-one
Clinical data
Identifiers
617720-02-2
PubChem CID 9865375
ChemSpider 8041067 Yes
Synonyms HT-0712, IPL 455,903
Chemical data
Formula C25H31NO3
393.53 g/mol
 Yes (what is this?)  (verify)

HT-0712 also known as IPL-455903,[1] is an experimental cognitive enhancing drug (nootropic) which is currently undergoing clinical trials. It is currently being licensed by Helicon Therapeutics in San Diego, California. It was originally discovered and tested as part of a preclinical anti-inflammatory program by Inflazyme Pharmaceuticals.[2]

Mechanism of action

HT-0712 appears to act as a PDE4 inhibitor, thereby increasing cAMP levels. When cAMP levels are increased in neurons, this may trigger activation of cAMP response element-binding proteins (CREB). CREBs are transcription factors involved in the formation of long-term memory.[2]

The side effects of the drug are not yet fully known.

Medical use

Middle-aged people, seniors, and possibly those suffering from dementia, who have a hard time remembering everyday events, can possibly benefit from this drug.

Performance enhancing use

Many students may be inclined to use nootropics for school and college life for exams and finals. This could also be an effective alternative or adjunctive to the use of caffeine as a study aid.

References

  1. ↑ Giembycz MA (October 2008). "Can the anti-inflammatory potential of PDE4 inhibitors be realized: guarded optimism or wishful thinking?". Br. J. Pharmacol. 155 (3): 288–90. doi:10.1038/bjp.2008.297. PMC 2567889. PMID 18660832.
  2. ↑ 2.0 2.1 MacDonald E, Van der Lee H, Pocock D et al. (2007). "A novel phosphodiesterase type 4 inhibitor, HT-0712, enhances rehabilitation-dependent motor recovery and cortical reorganization after focal cortical ischemia". Neurorehabil Neural Repair 21 (6): 486–96. doi:10.1177/1545968307305521. PMID 17823313.

External links